Citigroup Downgrades Tandem Diabetes Care to Neutral, Lowers Price Target to $33
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst Joanne Wuensch has downgraded Tandem Diabetes Care (NASDAQ:TNDM) from Buy to Neutral and lowered the price target from $45 to $33.
August 04, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tandem Diabetes Care has been downgraded from Buy to Neutral by Citigroup, with a lowered price target from $45 to $33.
The downgrade from Buy to Neutral by Citigroup indicates a less optimistic outlook for Tandem Diabetes Care. The lowered price target from $45 to $33 suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100